1. Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria.
- Author
-
Agada-Amade, Yakubu Adole, Ogbuabor, Daniel Chukwuemeka, Obikeze, Eric, Eboreime, Ejemai, and Onwujekwe, Obinna Emmanuel
- Subjects
HEMODIALYSIS patients ,COST benefit analysis ,CHRONIC kidney failure ,NATIONAL health insurance ,SECONDARY analysis ,BUDGET - Abstract
Background: Significant gaps in scholarship on the cost-benefit analysis of haemodialysis exist in low-middle-income countries, including Nigeria. The study, therefore, assessed the cost-benefit of haemodialysis compared with comprehensive conservative care (CCC) to determine if haemodialysis is socially worthwhile and justifies public funding in Nigeria. Methods: The study setting is Abuja, Nigeria. The study used a mixed-method design involving primary data collection and analysis of secondary data from previous studies. We adopted an ingredient-based costing approach. The mean costs and benefits of haemodialysis were derived from previous studies. The mean costs and benefits of CCC were obtained from a primary cross-sectional survey. We estimated the benefit-cost ratios (BCR) and net benefits to determine the social value of the two interventions. Results: The net benefit of haemodialysis (2,251.30) was positive, while that of CCC was negative (-1,197.19). The benefit-cost ratio of haemodialysis was 1.09, while that of CCC was 0.66. The probabilistic and one-way sensitivity analyses results demonstrate that haemodialysis was more cost-beneficial than CCC, and the BCRs of haemodialysis remained above one in most scenarios, unlike CCC's BCR. Conclusion: The benefit of haemodialysis outweighs its cost, making it cost-beneficial to society and justifying public funding. However, the National Health Insurance Authority requires additional studies, such as budget impact analysis, to establish the affordability of full coverage of haemodialysis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF